Tribun Health Achieves ISO/IEC 27001 Certification, Strengthening Commitment to Data Security in Digital Pathology
Tribun Health, a leader in digital pathology software and AI-powered diagnostic solutions, is proud to announce that it has been awarded the ISO/IEC 27001 certification-an internationally recognized standard for information security management systems (ISMS).
This achievement underscores Tribun Health's ongoing commitment to the highest standards of data protection, patient confidentiality, and operational excellence. In a field where security and privacy are non-negotiable, ISO 27001 certification validates that the company has implemented a robust framework to identify, manage, and reduce risks to sensitive information.
"Our clients trust us with more than just images-they trust us with lives," said Zina Hamoumi, Chief Operating Officer at Tribun Health. "Achieving ISO 27001 reflects the discipline, structure, and dedication our teams bring to protecting that trust every single day."
"This certification is not just a badge-it's a reflection of our core values," added Jean-François Pomerol, CEO of Tribun Health. "As we continue expanding globally, we remain deeply committed to earning and maintaining the confidence of our partners, customers, and the patients they serve."
Used by pathology labs, hospitals, and healthcare networks worldwide, Tribun Health's CaloPix® platform manages millions of digital slides annually. As data volumes grow and collaboration across institutions increases, the need for stringent, transparent security measures becomes even more critical. ISO 27001 certification confirms that Tribun Health meets those standards, offering peace of mind to healthcare professionals and IT departments alike.
Tribun Health continues to expand its footprint across Europe, North America and other regions, providing digital pathology platforms that are not only innovative but also safe and dependable. This certification builds on Tribun Health's long-standing commitment to data security, offering formal recognition of the rigorous controls already in place.
About Tribun Health
Tribun Health is a global leader in digital pathology, offering award-winning solutions that improve workflow efficiency, diagnostic accuracy, and patient outcomes. We assist hospitals and laboratories in transitioning from glass slide pathology to fully digital solutions, leveraging AI and data-driven technology to enhance precision and reduce turnaround times. Our mission is simple: to ensure every cancer patient receives a timely and informed diagnosis-because every moment counts. By advancing pathology with cutting-edge innovations, we are shaping the future of cancer care. For more information, visit Tribun Health and follow us on LinkedIn and X.
Contact Information
Andreia Beyer
VP, Global Marketing & Managing Director, North America
abeyer@tribun.health
+1 (416) 565-0474
SOURCE: Tribun Health
press release
This story was originally published May 6, 2025 at 8:06 AM.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
6 hours ago
- Business Wire
MedX Health Corp. Names John Gevisser as Chief Executive Officer
MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. ('MedX' or the 'Company') (TSXV: MDX), the global leader in teledermatology solutions, confirms the appointment of John Gevisser as the Company's Chief Executive Officer, effective immediately. Mr. Gevisser previously held the position of Chief Digital Officer at Health Partners Group, the United Kingdom's largest provider of occupational health services, where he led the company's technology and data strategy. He also oversaw their strategic partnerships and operationalized MedX's UK pilot programs. Before that, he served as Vice President of Growth & Development at Vitality Group in the United States, where he was responsible for commercializing Vitality's direct-to-consumer network and managing its global partnership with Apple Health and Apple Watch. Vitality operates the world's largest wellness platform. As MedX's CEO, Gevisser will focus on expanding MedX's international footprint, advancing the commercialization of its technology platform, and accelerating revenue-generating opportunities. 'John brings deep expertise in digital health and a global perspective that will prove invaluable as we scale MedX's operations,' said Mike Druhan, MedX President, Dermatology Services. 'His ability to execute international growth strategies and navigate an evolving healthcare landscape positions MedX for long-term success.' 'Skin cancer is a largely preventable condition, and employers and insurers are increasingly adopting preventative strategies to reduce the costs of workplace absenteeism,' said John Gevisser. 'As a former client, I saw firsthand how seamlessly MedX's hardware and software delivered peace of mind and fast-tracked access to dermatologists for hundreds of UK employees. This non-invasive technology platform is highly scalable, so the goal is to make this technology available to the at-risk population through occupational healthcare and insurance providers globally. The true strength of MedX lies not only in the speed of its assessments but also in the clinical accuracy of its results. These are exciting times for MedX as its unique solution to at-risk patients in the workplace is gaining market acceptance.' While passing over the CEO role to Mr. Gevisser, Stephen Lockyer will remain as President of MedX. 'The Board and shareholders of MedX are immensely grateful to Stephen, who stepped up as a Director, CEO and President in 2023 and has been a very significant contributor to the development and advances made by the Company since that time,' said Ken McKay, Chairman of the Board. About MedX Health Corp. MedX Health Corp., headquartered in Ontario, Canada, is a leader in non-invasive skin assessment and teledermatology. Its proprietary SIAscopy® technology, integrated into the DermSecure® platform, enables pain-free, accurate imaging of skin lesions for rapid dermatologist review. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne, for use in Canada, the U.S., Australia, New Zealand, the United Kingdom, the European Union and Turkey. MedX's advanced telemedicine platform enables healthcare professionals to quickly and accurately assess suspicious moles, lesions, and other skin conditions through its proprietary imaging technology, SIAscopy®, and its secure, cloud-based patient management system, DermSecure®. SIAscopy® is the only technology capable of capturing five high-resolution images, including four spectrophotometric scans that penetrate 2mm below the skin's surface. Visit: Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This Media Release may contain forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
Business Wire
7 hours ago
- Business Wire
SimplyTest Oral Health Launches Implant-Specific Salivary Test
SALT LAKE CITY--(BUSINESS WIRE)-- SimplyTest®, a leader in salivary screening solutions, today announced the launch of SimplyTest Oral Health-IMPLANT, a new molecular test designed to detect microbial species linked to peri-implant disease and implant failure. This test is the latest addition to the company's growing SimplyTest Oral Health line, which also includes SimplyTest Oral Health-PERIO and others. With SimplyTest Oral Health-IMPLANT, clinicians now have a fast, noninvasive way to identify the microbial risks before failure occurs. It's another step forward in our mission to elevate patient care through precision-based oral health solutions. According to a comprehensive review published in Cureus in 2022, infection is the most frequent and preventable cause of dental implant failure. SimplyTest Implant is engineered to detect eight high-risk pathogens, which include Porphyromonas gingivalis (Pg), Treponema denticola (Td), Tannerella forsythia (Tf), Prevotella intermedia (Pi), Fusobacterium nucleatum (Fn), Fusobacterium animalis (Fa), Candida albicans (Ca) and Pseudomonas aeruginosa (Pa). These organisms are recognized contributors to inflammation, tissue degradation and systemic immune response, often without visible early symptoms. 'Microbial infections are a major cause of implant-related complications,' said Joel Peek, Ph.D., SimplyTest Founder and Scientific Advisory Board Chair. 'With SimplyTest Oral Health-IMPLANT, clinicians now have a fast, noninvasive way to identify the microbial risks before failure occurs. It's another step forward in our mission to elevate patient care through precision-based oral health solutions.' Designed for chairside use or at-home collection, IMPLANT leverages a proprietary saliva preservation and analysis system. Results are delivered within 24 to 48 hours after the sample is received at the lab via a secure clinical portal, with pathogen-specific insights to support diagnostic conversations and treatment planning. 'The SimplyTest Oral Health line is part of a broader effort to redefine the standard of care in dentistry and systemic healthcare by empowering providers with tools that reveal the root causes of oral and systemic conditions,' said Justin Hunt, CEO of Spectrum Health Science. 'The IMPLANT test expands our platform's reach to support preventative implant care, surgical planning and cost-efficient treatment, which are key concerns for both clinicians and care organizations. It's a strong example of how SimplyTest equips providers with timely insights that improve patient outcomes and help reduce avoidable expenses.' Healthcare professionals can learn more about the IMPLANT offering and request materials at About SimplyTest SimplyTest® is redefining the starting point of care through next-generation salivary science. The SimplyTest platform delivers fast, noninvasive screenings that empower health care providers, functional medicine practitioners and dental professionals to detect microbial risks earlier, personalize treatment with precision and connect oral health to whole-body outcomes. Built on the belief that better diagnostics lead to better outcomes, SimplyTest is advancing a smarter, data-driven model of dentistry where early insight is the first step in personalized care. To learn more, visit
Associated Press
11 hours ago
- Associated Press
Wel-Bloom Biotech Launches Wel-ROS6. Black Crystal Roselle Sparks a Surge in High-Concentration Anthocyanins
TAIPEI, TAIWAN - Media OutReach Newswire - 22 July 2025 - Taiwan's leading jelly supplement manufacturer, Wel-Bloom Biotech, recently co-hosted an anthocyanin-focused seminar with LEARN EATiNG, one of the most renowned nutritionist teams in Taiwan. The event highlighted trending international ingredients alongside Taiwan's own Black Crystal Roselle. Attracting around 300 nutrition professionals both online and onsite, the seminar reflected strong industry interest and high expectations for the future of anthocyanin innovation. Wel-Bloom Biotech and the LEARN EATiNG nutrition team host a high-profile seminar. (Image/Wel-Bloom) In recent years, the health supplement market has seen rapid growth, accompanied by a shift in consumer priorities. Today's consumers increasingly believe that 'choosing the right ingredients matters more than simply taking more,' a mindset that is driving innovation in ingredient formulation. According to the 2024 Top 30 Dietary Trends Report, there is growing interest in the synergistic effects of ingredient combinations. For instance, pairing anthocyanins with fish oil offers comprehensive support for overall health, while combining them with collagen enhances beauty and skin wellness. The Black Crystal Roselle, grown locally in Taiwan, contains naturally high levels of anthocyanins and has recently drawn growing interest in the health supplement field for its promising nutritional potential. As one of the keynote speakers, Wel-Bloom Biotech introduced Wel-ROS6®—a proprietary botanical ingredient derived from Black Crystal Roselle. Developed using triple-patented technology, it is cultivated through natural farming methods and smallholder contract farming to ensure consistent quality and traceability. Laboratory data shows that Wel-ROS6® contains 17.7 times more total anthocyanins than standard commercial roselle. Additionally, total phenolic acids and flavonoids are elevated by 1.9 times and 1.3 times, respectively—highlighting its rich phytochemical profile and high functional value. (See Note 1) The event also featured the Food Industry Research and Development Institute's newly proposed 'Food Value Equation": Value = (Sensory Perception × Functional Technology × User Experience) × Amplification Multiplier. This formula highlights the importance of balancing sensory appeal, technological innovation, and user experience—emphasizing that all three elements are essential to creating meaningful value in food products. To meet growing consumer demands for convenience and palatability in health supplements, product development is increasingly focused on factors such as absorption efficiency, flavor optimization, and sustainable sourcing. The rise of 'tasty' health products reflects a major trend in preventive wellness—perfectly aligned with today's mindset of 'eating less, supplementing smarter.' Through its one-stop CDMO (Contract Development and Manufacturing Organization) services, Taiwan's local agriculture can now be transformed from raw materials into globally market-ready products that seamlessly integrate into everyday life. Wel-ROS6®, backed by the support of over 300 health professionals, will be featured alongside other cutting-edge botanical ingredients at the 2025 BIO Asia–Taiwan Exhibition and Vitafoods Asia. We warmly invite you to visit our booth and explore partnership opportunities with Wel-Bloom Biotech to co-create the next generation of best-selling health supplements. Note 1: Testing commissioned to the Food Industry Research and Development Institute: Independent testing by the Forecast Research Lab: Hashtag: #Welbloom #Wel-ROS6 #BlackCrystalRoselle The issuer is solely responsible for the content of this announcement.
